Cantex Pharmaceuticals to Present at The 14th Annual BIO Investor Forum

News provided by

Oct 14, 2015, 04:05 ET

WESTON, Fla., Oct. 14, 2015 /PRNewswire/ -- Cantex Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced that it will present at The 14th Annual BIO Investor Forum to be held October 20-21, 2015 at the Parc 55 San Francisco.

Stephen G. Marcus, M.D., Chief Executive Officer of Cantex, will provide an overview of the company's business and clinical-stage development pipeline, including its lead product, CX-01, during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Event:		The 14th Annual BIO Investor Forum
Date:		Tuesday, October 20, 2015
Presentation Time:		10:30 am (Pacific Time)
Location:		Parc 55 San Francisco, Fillmore Room

Dr. Marcus' presentation will be webcast live and made available as an archive on Cantex Pharmaceuticals' website, www.cantex.com.

About Cantex Pharmaceuticals, Inc.

Cantex is a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment. The Company's lead product candidate, CX-01, is in clinical development for acute myeloid leukemia and lung cancer. CX-01 is a rationally designed complex carbohydrate that blocks the activity of several chemokines that support the growth and spread of cancer and its resistance to treatment and that contribute to the delay of bone marrow recovery after chemotherapy. For more information, please visit www.cantex.com.

For Cantex Pharmaceuticals, Inc.:

Media / Investor Contacts:

Stephen G. Marcus, M.D.

Juan F. Rodriguez

954-315-3660

[email protected]

Janine McCargo / Tirth Patel

Tiberend Strategic Advisors, Inc.

646-604-5150 / 212-375-2681

[email protected]

SOURCE Cantex Pharmaceuticals, Inc.